Overview
Increased Dose of Icotinib in Advanced None Small Cell Lung Cancer Patients After Routine Gefitinib Therapy
Status:
Suspended
Suspended
Trial end date:
2016-12-01
2016-12-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
To evaluate the efficacy and safety of increased dose of icotinib in advanced NSCLC patients who progressed after gefitinib therapy.Phase:
Phase 4Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Betta Pharmaceuticals Co., Ltd.
Betta Pharmaceuticals Co.,Ltd.Treatments:
Gefitinib
Criteria
Inclusion Criteria:- Histologically or cytologically confirmed local advanced or metastatic stage IIIB/IV
NSCLC.
- Have been treated with gefitinib and achieved completed response, partial remission,
or stable disease within 3 months after first dose of gefitinib.
- At least one measurable lesion according to Response Evaluation Criteria in Solid
Tumors.
- Signed and dated informed consent before the start of specific protocol procedures.
Exclusion Criteria:
- Allergic to icotinib.
- Gefitinib excepted, experience of Anti-tumor Monoclonal Antibody or small molecular
compounds therapy such as erlotinib or Cetuximab.
- Severe systemic disease out of control such as unstable or uncompensated
respiratory,cardiac,liver,renal diseases.